RxDoctor Payments Data

Pratik Bhattacharya, MD

Neurology · Pontiac, MINPI 1528212768

Payments from drug & device makers

$11,798in general payments, 2019–2025

Across 572 payments — averaging $20.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$1K
  • UCB, Inc.$1K
  • Teva Pharmaceuticals USA, Inc.$763
  • Lundbeck LLC$656
  • Biogen$648
  • AbbVie$640
  • plus $7K from 35 others

What the payments were for

  • Consulting fees$1501%
  • Food & beverage$11,43997%
  • Education$2092%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,798 in reported general payments places this provider in the 75th percentile of 652 neurology providers in Michigan.

See all neurology providers in Michigan

Medicare billing

Part B allowed, 2024
$190,663
Medicare patients
639
Services billed
1,676

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate42$329,077
GammakedImmune Globul G/Gly/Iga Avg 4626$214,207
Rebif RebidoseInterferon Beta-1a/Albumin13$131,716
UbrelvyUbrogepant30$50,836
Dimethyl Fumarate29$42,736
EliquisApixaban37$41,845
NuedextaDextromethorphan Hbr/Quinidine24$36,351
Nurtec OdtRimegepant Sulfate15$22,482
BriviactBrivaracetam14$21,295
LyricaPregabalin13$20,969
Rivastigmine52$15,456
Emgality SyringeGalcanezumab-Gnlm17$12,559
Carbidopa-LevodopaCarbidopa/Levodopa153$9,000
Emgality PenGalcanezumab-Gnlm12$8,906
Teriflunomide13$7,768

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$1,276$329,07742 claims
PfizerEliquis, Nurtec Odt, Lyrica$588$85,29665 claims
AbbVieUbrelvy$640$50,83630 claims
Avanir Pharmaceuticals, Inc.Nuedexta$44$36,35124 claims
UCB, Inc.Briviact$1,138$21,29514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 652 neurology providers in Michigan.

Other neurology in Pontiac

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →